SEC Form 4 · accession 0001181431-15-007226

Intra-Cellular Therapies, Inc. · ITCI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Vice President, Drug Discovery

Period of report

May 19, 2015

Accepted (ET)

May 20, 2015 · 5:19 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001567514

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	May 19, 2015	M	12,500	$0.60	A	116,500	D
Common Stock	May 19, 2015	M	12,500	$1.36	A	129,000	D
Common Stock	May 19, 2015	M	12,500	$1.50	A	141,500	D
Common Stock	May 19, 2015	M	10,000	$1.50	A	151,500	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (right to buy)^F1	$0.60	May 19, 2015	M	12,500	D	—	Dec 14, 2015	Common Stock	12,500	D
Stock Option (right to buy)^F1	$1.36	May 19, 2015	M	12,500	D	—	Dec 5, 2016	Common Stock	12,500	D
Stock Option (right to buy)^F1	$1.50	May 19, 2015	M	12,500	D	—	Dec 12, 2017	Common Stock	12,500	D
Stock Option (right to buy)^F1	$1.50	May 19, 2015	M	10,000	D	—	Dec 18, 2018	Common Stock	10,000	D